This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.

Pipeline Overview

Explore our pipeline of investigational medicines, featuring therapies designed to inhibit cancer-driving molecular targets in genetically defined pediatric and adult patient populations.



PRECLINICAL
EARLY STAGE CLINICAL DEVELOPMENT
LATE STAGE CLINICAL DEVELOPMENT
REGULATORY SUBMISSION
APPROVED
VITRAKVI® (larotrectinib) - TRK Inhibitor
EU*
USA**
LOXO-292 - Cancers Harboring RET Fusions or Activating RET Mutations
LOXO-195 - Second Generation TRK Inhibitor for Potential Acquired Resistance
LOXO-305 - Non-Covalent BTK Inhibitor for B-cell Cancers
Second Generation RET Inhibitor for Potential Acquired Resistance
FGFR Program - Cancers Harboring Alterations of Fibroblast Growth Factor Receptor (FGFR)

For comprehensive details about these clinical trials, please refer to clinicaltrials.gov.

Policy for Access to Investigational Agents

Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology's Policy for Access to Investigational Agents describes the principles and government regulations that the company will follow when considering a request.